Skip to content
VuFind
Login
Language
English
اللغة العربية
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Selected features and coeffici...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Selected features and coefficients after screening.
<p>Selected features and coefficients after screening.</p>
Saved in:
Bibliographic Details
Main Author:
Yiran Li (1818355)
(author)
Other Authors:
Zonghan Liu (12521164)
(author)
,
Yi Qian (466487)
(author)
,
Kang Wang (415359)
(author)
,
Yijun Gu (16620079)
(author)
,
Yan Chen (4308)
(author)
,
Haozheng Jiang (20666265)
(author)
,
Shuqun Cheng (151531)
(author)
,
Dong Jiang (159266)
(author)
Published:
2025
Subjects:
Biochemistry
Medicine
Genetics
Molecular Biology
Pharmacology
Biotechnology
Marine Biology
Cancer
Infectious Diseases
Plant Biology
Virology
unresectable hepatocellular carcinoma
combined targeted therapy
atezolizumab plus bevacizumab
separate ur models
predict treatment efficacy
xlink ">
validation group
two groups
train group
therapeutic efficacy
radiomics models
particularly highlighting
model performance
effective treatment
cutoff value
assessment methods
Tags:
Add Tag
No Tags, Be the first to tag this record!
Holdings
Description
Comments
Similar Items
Staff View
Similar Items
The Flow chart is an overview of the screening process(UR = Ultrasounic-radiomics).
by: Yiran Li (1818355)
Published: (2025)
Extraction of pre-treatment and post-treatment ultrasound radiomics features.
by: Yiran Li (1818355)
Published: (2025)
Evaluation of post-treatment models using different machine learning algorithms.
by: Yiran Li (1818355)
Published: (2025)
Evaluation of pre-treatment models using different machine learning algorithms.
by: Yiran Li (1818355)
Published: (2025)
Baseline characteristics and treatment of adverse reactions of patients in two cohorts.
by: Yiran Li (1818355)
Published: (2025)
Pre-treatment US model and post-treatment US model predict patient survival: 10 KM (divided into high and low-risk groups based on rad-score cutoff values of 0.528 (train) and 0.528 (test)).
by: Yiran Li (1818355)
Published: (2025)
Evaluate the predictive performance of the model: ROC analysis of models on rad signature in pre-treatment US model (A) and post-treatment US model (B); Decision curve of in train and test cohort in pre-treatment US model (C and D) and post-treatment US (E and F).
by: Yiran Li (1818355)
Published: (2025)
The area under the curve (AUC) of the radiomics signature model on both the train (A and B) and test cohorts (C and D).
by: Yiran Li (1818355)
Published: (2025)
Raw data.
by: Yiran Li (1818355)
Published: (2025)
Data Sheet 1_Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC.pdf
by: Hee Sun Cho (18067327)
Published: (2025)
Flowchart of study selection.
by: Heng Xiang (679982)
Published: (2025)
Summary of cost and outcome results in the base-case analysis.
by: Heng Xiang (679982)
Published: (2025)
Key Model Inputs.
by: Heng Xiang (679982)
Published: (2025)
Cost-effectiveness acceptability curves.
by: Heng Xiang (679982)
Published: (2025)
Markov model.
by: Heng Xiang (679982)
Published: (2025)
Scatter plot of probabilistic sensitivity analyses.
by: Heng Xiang (679982)
Published: (2025)
Tornado diagram of one-way sensitivity analyses.
by: Heng Xiang (679982)
Published: (2025)
Risk of bias summary.
by: Heng Xiang (679982)
Published: (2025)
Network graph of treatment comparison.
by: Heng Xiang (679982)
Published: (2025)
Image1_Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.JPEG
by: Hongfu Cai (9732137)
Published: (2024)
Table1_Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.DOCX
by: Hongfu Cai (9732137)
Published: (2024)
Data Sheet 1_Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma – a multicenter cohort study.pdf
by: Takaya Tabuchi (10634815)
Published: (2025)
Supplementary file 1_Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.docx
by: Yan Zhu (112437)
Published: (2025)
Table1_Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination.DOCX
by: Takahiro Niimura (7836779)
Published: (2024)
Table 6_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Table 5_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Table 4_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Table 2_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Table 3_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Table 1_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.docx
by: Rui Fang (138089)
Published: (2025)
Data Sheet 1_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.pdf
by: Rui Fang (138089)
Published: (2025)
Data Sheet 2_Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.pdf
by: Rui Fang (138089)
Published: (2025)
DataSheet1_Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy.ZIP
by: Yujing Xin (12202626)
Published: (2024)
Data Sheet 1_FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.pdf
by: Yan-Cen Lu (13718623)
Published: (2024)
Data Sheet 2_FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.pdf
by: Yan-Cen Lu (13718623)
Published: (2024)
Image 1_Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.tif
by: Junfeng Bu (12439798)
Published: (2025)
Table 1_Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.docx
by: Junfeng Bu (12439798)
Published: (2025)
Image 2_Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.tif
by: Junfeng Bu (12439798)
Published: (2025)
Table 1_Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study.docx
by: Yan-Song Lin (13769381)
Published: (2025)
Data Sheet 1_Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.docx
by: Lichang Huang (21412778)
Published: (2025)
Prev
Next
Similar Items
The Flow chart is an overview of the screening process(UR = Ultrasounic-radiomics).
by: Yiran Li (1818355)
Published: (2025)
Extraction of pre-treatment and post-treatment ultrasound radiomics features.
by: Yiran Li (1818355)
Published: (2025)
Evaluation of post-treatment models using different machine learning algorithms.
by: Yiran Li (1818355)
Published: (2025)
Evaluation of pre-treatment models using different machine learning algorithms.
by: Yiran Li (1818355)
Published: (2025)
Baseline characteristics and treatment of adverse reactions of patients in two cohorts.
by: Yiran Li (1818355)
Published: (2025)
